Epidermal growth factor receptor tyrosine kinase inhibitors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-05-11

AUTHORS

M Ranson

ABSTRACT

Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development. More... »

PAGES

2250-2255

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873

DOI

http://dx.doi.org/10.1038/sj.bjc.6601873

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021715784

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15150574


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein-Tyrosine Kinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 4BX, Manchester, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 4BX, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ranson", 
        "givenName": "M", 
        "id": "sg:person.01124372241.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124372241.32"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1206388", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004564925", 
          "https://doi.org/10.1038/sj.onc.1206388"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-05-11", 
    "datePublishedReg": "2004-05-11", 
    "description": "Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6601873", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "90"
      }
    ], 
    "keywords": [
      "tyrosine kinase inhibitors", 
      "epidermal growth factor receptor", 
      "kinase inhibitors", 
      "epidermal growth factor receptor tyrosine kinase inhibitors", 
      "growth factor receptor tyrosine kinase inhibitors", 
      "receptor tyrosine kinase inhibitors", 
      "EGFR tyrosine kinase inhibitors", 
      "cell lung cancer", 
      "impressive tumor regression", 
      "growth factor receptor", 
      "lung cancer", 
      "tumor regression", 
      "surrogate marker", 
      "epithelial tumors", 
      "clinical development", 
      "promising anticancer agent", 
      "monoclonal antibodies", 
      "factor receptor", 
      "translational research", 
      "anticancer agents", 
      "inhibitors", 
      "patients", 
      "metastasis", 
      "tumors", 
      "cancer", 
      "receptors", 
      "antibodies", 
      "angiogenesis", 
      "current status", 
      "invasion", 
      "proliferation", 
      "markers", 
      "activation", 
      "status", 
      "review", 
      "regression", 
      "agents", 
      "development", 
      "activity", 
      "need", 
      "future development", 
      "research", 
      "approach", 
      "main approaches"
    ], 
    "name": "Epidermal growth factor receptor tyrosine kinase inhibitors", 
    "pagination": "2250-2255", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021715784"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6601873"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15150574"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6601873", 
      "https://app.dimensions.ai/details/publication/pub.1021715784"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_393.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6601873"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      21 PREDICATES      79 URIs      70 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6601873 schema:about N188a72f5d5944d979caf0b833fa2ff51
2 N3b0c2502795d41bf9274ec6edbb06a17
3 N7607e9c30fd34c16841cc13b83353c0d
4 N89433ac862064bb286266a547ed9661f
5 N8a05eeb4e07741559336a5b671283e4f
6 N944d55cb509d4abfb35b273c48b12510
7 Nd25a931bffc54a75b6a123da5967032a
8 Ndbb2f4a5aa72490aad640725b0795004
9 Nf159d45bb06b48edbe06dc661e5f8cb9
10 anzsrc-for:11
11 anzsrc-for:1112
12 schema:author N9d7a89f6f33e4328a36d5d3ff2cd71b3
13 schema:citation sg:pub.10.1038/sj.onc.1206388
14 schema:datePublished 2004-05-11
15 schema:datePublishedReg 2004-05-11
16 schema:description Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development.
17 schema:genre article
18 schema:isAccessibleForFree true
19 schema:isPartOf N0338ab4e03a0497791f56e806893c93e
20 Nbe3ab4d71db2462d979db8522510c886
21 sg:journal.1017082
22 schema:keywords EGFR tyrosine kinase inhibitors
23 activation
24 activity
25 agents
26 angiogenesis
27 antibodies
28 anticancer agents
29 approach
30 cancer
31 cell lung cancer
32 clinical development
33 current status
34 development
35 epidermal growth factor receptor
36 epidermal growth factor receptor tyrosine kinase inhibitors
37 epithelial tumors
38 factor receptor
39 future development
40 growth factor receptor
41 growth factor receptor tyrosine kinase inhibitors
42 impressive tumor regression
43 inhibitors
44 invasion
45 kinase inhibitors
46 lung cancer
47 main approaches
48 markers
49 metastasis
50 monoclonal antibodies
51 need
52 patients
53 proliferation
54 promising anticancer agent
55 receptor tyrosine kinase inhibitors
56 receptors
57 regression
58 research
59 review
60 status
61 surrogate marker
62 translational research
63 tumor regression
64 tumors
65 tyrosine kinase inhibitors
66 schema:name Epidermal growth factor receptor tyrosine kinase inhibitors
67 schema:pagination 2250-2255
68 schema:productId N03f44f08759f403eaf9725a3f590ad18
69 N63af683f5f8849a492c3f67c1adb54e5
70 N6785c6fb51c84ff4bc3ba528b4a035f2
71 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021715784
72 https://doi.org/10.1038/sj.bjc.6601873
73 schema:sdDatePublished 2022-09-02T15:50
74 schema:sdLicense https://scigraph.springernature.com/explorer/license/
75 schema:sdPublisher N81297f2cc2f1408f8b081d68852acd3e
76 schema:url https://doi.org/10.1038/sj.bjc.6601873
77 sgo:license sg:explorer/license/
78 sgo:sdDataset articles
79 rdf:type schema:ScholarlyArticle
80 N0338ab4e03a0497791f56e806893c93e schema:volumeNumber 90
81 rdf:type schema:PublicationVolume
82 N03f44f08759f403eaf9725a3f590ad18 schema:name pubmed_id
83 schema:value 15150574
84 rdf:type schema:PropertyValue
85 N188a72f5d5944d979caf0b833fa2ff51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Biomarkers, Tumor
87 rdf:type schema:DefinedTerm
88 N3b0c2502795d41bf9274ec6edbb06a17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Carcinoma, Non-Small-Cell Lung
90 rdf:type schema:DefinedTerm
91 N63af683f5f8849a492c3f67c1adb54e5 schema:name dimensions_id
92 schema:value pub.1021715784
93 rdf:type schema:PropertyValue
94 N6785c6fb51c84ff4bc3ba528b4a035f2 schema:name doi
95 schema:value 10.1038/sj.bjc.6601873
96 rdf:type schema:PropertyValue
97 N7607e9c30fd34c16841cc13b83353c0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Humans
99 rdf:type schema:DefinedTerm
100 N81297f2cc2f1408f8b081d68852acd3e schema:name Springer Nature - SN SciGraph project
101 rdf:type schema:Organization
102 N89433ac862064bb286266a547ed9661f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Lung Neoplasms
104 rdf:type schema:DefinedTerm
105 N8a05eeb4e07741559336a5b671283e4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Protein-Tyrosine Kinases
107 rdf:type schema:DefinedTerm
108 N944d55cb509d4abfb35b273c48b12510 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Antineoplastic Agents
110 rdf:type schema:DefinedTerm
111 N9d7a89f6f33e4328a36d5d3ff2cd71b3 rdf:first sg:person.01124372241.32
112 rdf:rest rdf:nil
113 Nbe3ab4d71db2462d979db8522510c886 schema:issueNumber 12
114 rdf:type schema:PublicationIssue
115 Nd25a931bffc54a75b6a123da5967032a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Antibodies, Monoclonal
117 rdf:type schema:DefinedTerm
118 Ndbb2f4a5aa72490aad640725b0795004 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Clinical Trials as Topic
120 rdf:type schema:DefinedTerm
121 Nf159d45bb06b48edbe06dc661e5f8cb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name ErbB Receptors
123 rdf:type schema:DefinedTerm
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
128 schema:name Oncology and Carcinogenesis
129 rdf:type schema:DefinedTerm
130 sg:journal.1017082 schema:issn 0007-0920
131 1532-1827
132 schema:name British Journal of Cancer
133 schema:publisher Springer Nature
134 rdf:type schema:Periodical
135 sg:person.01124372241.32 schema:affiliation grid-institutes:None
136 schema:familyName Ranson
137 schema:givenName M
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124372241.32
139 rdf:type schema:Person
140 sg:pub.10.1038/sj.onc.1206388 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004564925
141 https://doi.org/10.1038/sj.onc.1206388
142 rdf:type schema:CreativeWork
143 grid-institutes:None schema:alternateName Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 4BX, Manchester, UK
144 schema:name Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 4BX, Manchester, UK
145 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...